Pulse Biosciences

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pulse Biosciences pivots to cardiac tech, eyes FDA device market

Pulse Biosciences reported financials, highlighted cardiac ablation technology, and pivoted towards an FDA-approved device for cellular repair, showcasing adaptability and strategic focus.
The company faces challenges in transitioning focus areas and managing financial projections but has strengths in innovation, market potential, and strategic autonomy.
Opportunities lie in licensing breakthrough technologies, commercial partnerships, regulatory milestones, and market disruption, positioning Pulse Biosciences for growth and success.
Overall, Pulse Biosciences' strategic shifts, financial prudence, and focus on innovation present a promising outlook for sustainable growth and market expansion.

Pulse Biosciences advances cardiac ablation tech with strong financials

Pulse Biosciences made notable progress in Q1 2023, showcasing financial improvements, key leadership additions, and advancements in developing innovative cardiac ablation technologies.
While facing challenges in clinical validation and regulatory processes, the company's strategic roadmap and focus on nsPFA technology position them well for future growth and success.
With a strong financial position, experienced leadership, and a clear vision for product development, Pulse Biosciences is poised to capitalize on the market opportunities in cardiac ablation.

Pulse Biosciences advances nsPFA technology in cardiac applications, boosts finances

Pulse Biosciences demonstrated strong progress in nsPFA technology for cardiac applications and showcased financial improvements.
While facing questions about study expansions and project exits, the company remains confident in its market position.
Opportunities lie in expanding nsPFA applications, leveraging positive feedback, and exploring strategic partnerships for growth.

Pulse Biosciences advances CellFX technology, reduces costs, eyes growth opportunities

Pulse Biosciences demonstrated strong performance in technology advancement, cost management, and stakeholder engagement, positioning the company for growth.
Despite challenges related to patent concerns, the company's focus on innovation, safety, and partnerships presents opportunities for expansion and market leadership.
With a solid financial position, strategic development goals, and a commitment to excellence, Pulse Biosciences is poised for continued success in the medical technology sector.

Pulse Biosciences advances innovative surgical technology with promising FDA clearances

Pulse Biosciences is optimistic about the future impact of its energy technology on surgery and emphasizes the importance of strong support structures for successful product launches.

Pulse Biosciences excels in Q2, poised for transformative medical advancements

Pulse Biosciences' Q2 2024 performance reflects progress, financial strength, and strategic focus on pivotal clinical trials.
While facing challenges such as increased costs and operational complexities, the company is well-positioned to leverage opportunities in transformative medical technologies.
With a solid financial foundation, strong leadership, and innovative products, Pulse Biosciences is poised for continued growth and market success.
Navigating regulatory hurdles and market competition will be key as the company advances its nano-PFA technology in medical treatments.

Pulse Biosciences reports Q3 loss, strengthens balance sheet for growth

Pulse Biosciences' Q3 2024 earnings call highlighted progress in medical applications, a strengthened balance sheet, and a focus on pivotal clinical studies in 2025.
While facing challenges with increased expenses and net loss, the company's innovative technology and strategic fundraising efforts position it for future growth.
Opportunities lie in advancing clinical studies, expanding product applications, and solidifying its presence in the healthcare market through strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

American Assets

Akoya Biosciences Inc

American Vanguard

Cannae Hlds

Domo

Enviva Partners

National Vision Hlds

Globalstar

Heartland Express

I3 Verticals

MillerKnoll

PacWest Bancorp

Pebblebrook Hotel Trust

B. Riley Financial

Skillz

ACELYRIN Inc

SPDR S&P 500 ETF Trust

Stellar Bancorp Inc

StepStone Group

Washington Federal

Zumiez

After covering second-quarter corporate insider activity among mid-cap and large-caps, today's article will cover on the most interesting insider purchases for small-cap companies. Corporate insiders at American Assets Trust, National Vision, Skillz, Enviva, Heartland Express, and Zumiez have been buying significant amounts of shares, signaling confidence in their respective companies. Other notable insider activity among small-cap stocks includes B. Riley Financial, Cannae Holdings, i3 Verticals, whose CEOs have bought million worth of stock in the second quarter.

Strong Small-Cap Insider Buys: Q2 2023

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced today it will report financial results for the second quarter of 2023 after market close on Thursday, August 10, 2023. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call m.

Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced nsPFA will be featured in three presentations at the upcoming Heart Rhythm 2023 Annual Meeting in New Orleans, LA from May 19-21. “We are very encouraged that the preclinical work completed with our nsPFA devices will be featured among leading technologies at the prem.

Pulse Biosciences' Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting

Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Trip Taylor - Investor Relations Kevin Danahy - President & Chief Executive Officer Darrin Uecker - Chief Technology Officer Mike Koffler - Vice President of Finance Robert Duggan – Executive Chairman Conference Call Participants Robert Lovgren – Medical Hope Productions Operator Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the Pulse Biosciences First Quarter 2023 Earnings Conference Call.

Pulse Biosciences, Inc. (PLSE) Q1 2023 Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced financial results for the first quarter ended March 31, 2023. Business Updates Announced the appointment of Gansevoort “Gan” Dunnington, MD, as Chief Medical Officer, Cardiac Surgery; Dr. Dunnington is a key opinion leading cardiothoracic surgeon pioneering novel les.

Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced that it intends to deliver an irrevocable notice of redemption, on or about May 15, 2023, to redeem all of the common stock warrants that were issued as part of its June 9, 2022 rights offering which are still outstanding as of June 16, 2023 (the “Redemption Date”).

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced the appointment of Gansevoort “Gan” Dunnington, M.D. as its Chief Medical Officer. “On behalf of the Company, I am thrilled to welcome Dr. Dunnington to the Pulse Biosciences team,” said Kevin Danahy, Chief Executive Officer of.

Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology and proprietary CellFX System® for the treatment of atrial fibrillation, today announced that it has entered into a stock purchase agreement with Robert W. Duggan, an experienced life sciences executive and the Company's Executive Chairman, for the purchase of 10,022,937 shares of the Company's common stock at a price of $6.

Pulse Biosciences Announces $65 Million Private Placement

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, announced today it will report financial results for the first quarter of 2023 after market close on Thursday, May 11, 2023. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to th.

Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023

Pulse Biosciences Inc. (NASDAQ:PLSE ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Trip Taylor – Investor Relations Kevin Danahy – President and Chief Executive Officer Darrin Uecker – Chief Technology Officer Robert Duggan – Executive Chairman Conference Call Participants Robert Lovgren – Medical Hope Productions James Hollingsworth – Private Investor Operator Ladies and gentlemen, greetings, and welcome to the Pulse Biosciences' Fourth Quarter 2022 Earnings Conference Call. At this time all participants lines are in a listen-only mode.

Pulse Biosciences Inc. (PLSE) Q4 2022 Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, today announced financial results for the fourth quarter and full year ended December 31, 2022.

Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, announced today it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 30, 2023. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.

Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023

HAYWARD, Calif.--( BUSINESS WIRE )--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, today announced its technology will be highlighted in a poster presentation at the 28th Annual International AF Symposium meeting in Boston February 2–4.

Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium

Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor – Investor Relations, Gilmartin Group Kevin Danahy – President and Chief Executive Officer Darrin Uecker – Chief Technology Officer Sandy Gardiner – Executive Vice President and Chief Financial Officer Conference Call Participants Operator Greetings and welcome to Pulse Biosciences Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Pulse Biosciences, Inc. (PLSE) Q3 2022 Earnings Call Transcript

HAYWARD, Calif.--( BUSINESS WIRE )--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company and creator of the unique CellFX® System which harnesses and effectively controls the application of Nano-Pulse Stimulation™ (NPS™) to human cells and tissue for ablation in multiple therapeutic conditions, today announced financial results for the third quarter ended September 30, 2022.

Pulse Biosciences Reports Third Quarter 2022 Financial Results

Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced positive clinical data from an FDA approved Investigational Device Exempt treat and resect study on the use of NPS for low-risk basal cell carcinoma (BCC) lesions. An oral video presentation on the favorable results of performing the CellFX procedure for low-risk superficial and nod

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Spero Therapeutics

Alaunos Therapeutics

Hot penny stocks to add to your watch list this week. Is it time to buy?

Hot Penny Stocks To Watch As The Stock Market Crash Continues

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its CellFX System, expanding the indication for use to include the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-III. This specific indication clearance enhances the CellFX System's gen

Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced a shift in focus to advance its core technology. Pulse Biosciences is expanding strategic opportunities within healthcare, and anticipates a concentrated focus on cardiovascular applications, with potential expansion in oncology, gastroenterology, and other sectors where the Company

Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation

Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Darrin Uecker - President and Chief Executive Officer Kevin Danahy - Chief Commercial Officer Sandra Gardiner - Executive Vice President and Chief Financial Officer Conference Call Participants Jeremy Pearlman - Maxim Group LLC Swayampakula Ramakanth - H.C. Wainwright & Co, LLC Operator Greetings, and welcome to Pulse Biosciences Second Quarter 2022 Earnings Conference Call.

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2022 Results - Earnings Call Transcript

Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 0% and 52.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the second quarter ended June 30, 2022. Company Updates Continued active engagement and collaboration with the nine commercial clinics participating in the CellFX System utilization program. Received FDA 510(k) clearance of expanded energy settings for use with

Pulse Biosciences Reports Second Quarter 2022 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance of expanded energy settings for use with the family of CellFX System treatments tips in dermatology. “Pulse Biosciences is dedicated to providing dermatologists a superior solution for the treatment of benign lesion

Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2022 after market close on Wednesday, August 10, 2022. Company management will host a corresponding conference call beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-877-

News for Pulse Biosciences Stock (PLSE)